Biohaven (BHVN) | Financial Analysis & Statements
Biohaven Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-142.7M
Net Income
-145.6M
Balance Sheet Metrics
Total Assets
451.4M
Total Liabilities
399.4M
Shareholders Equity
52.1M
Debt to Equity
7.67
Cash Flow Metrics
Operating Cash Flow
-126.3M
Free Cash Flow
-130.7M
Revenue & Profitability Trend
Biohaven Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 635.1M | 795.9M | 373.3M | 437.1M | 181.5M |
| Selling, General & Administrative | 110.3M | 89.2M | 62.8M | 130.9M | 37.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 745.4M | 885.1M | 436.1M | 567.9M | 218.9M |
| Operating Income | -745.4M | -885.1M | -436.1M | -567.9M | -218.9M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 8.0M | 39.4M | 26.5M | -1.9M | 6.5M |
| Pre-tax Income | -737.4M | -845.7M | -409.6M | -569.8M | -212.4M |
| Income Tax | 1.4M | 735.0K | -1.4M | 438.0K | 1.4M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -738.8M | -846.4M | -408.2M | -570.3M | -213.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -735.5M | -877.3M | -429.1M | -566.5M | -217.5M |
| EPS (Basic) | - | $-9.28 | $-5.73 | $-12.75 | $-5.97 |
| EPS (Diluted) | - | $-9.28 | $-5.73 | $-12.75 | $-5.97 |
| Basic Shares Outstanding | - | 91234337 | 71200527 | 44741316 | 35822511 |
| Diluted Shares Outstanding | - | 91234337 | 71200527 | 44741316 | 35822511 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Biohaven Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 230.0M | 99.1M | 248.4M | 204.9M | 76.1M |
| Short-term Investments | 89.2M | 386.9M | 133.4M | 260.5M | 0 |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 2.2M | 508.0K | 12.1M | 19.3M | 2.1M |
| Total Current Assets | 368.3M | 538.5M | 442.4M | 587.0M | 94.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 45.1M | 36.7M | 31.9M | 37.6M | 5.2M |
| Goodwill | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M |
| Intangible Assets | 18.4M | 18.4M | 18.4M | 18.4M | 18.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.3M | 3.1M | 2.4M | 2.6M | 3.2M |
| Total Non-Current Assets | 83.1M | 76.6M | 70.8M | 74.8M | 47.2M |
| Total Assets | 451.4M | 615.1M | 513.2M | 661.8M | 142.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 11.6M | 18.0M | 15.6M | 10.7M | 4.8M |
| Short-term Debt | 5.8M | 3.8M | 3.3M | 3.0M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 42.7M | 84.7M | - | 11.7M | 3.6M |
| Total Current Liabilities | 115.9M | 154.2M | 55.4M | 90.0M | 41.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 278.9M | 32.8M | 27.6M | 30.6M | 2.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 4.6M | 4.7M | 2.2M | 2.4M | 2.6M |
| Total Non-Current Liabilities | 283.4M | 37.4M | 29.8M | 33.0M | 5.4M |
| Total Liabilities | 399.4M | 191.7M | 85.2M | 123.0M | 47.4M |
| Equity | |||||
| Common Stock | 1.9B | 1.7B | 887.5M | 615.7M | 0 |
| Retained Earnings | -2.1B | -1.3B | -499.3M | -91.1M | 0 |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 52.1M | 423.4M | 428.0M | 538.8M | 94.7M |
| Key Metrics | |||||
| Total Debt | 284.6M | 36.6M | 30.9M | 33.6M | 2.8M |
| Working Capital | 252.4M | 384.2M | 387.0M | 496.9M | 52.9M |
Balance Sheet Composition
Biohaven Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -738.8M | -846.4M | -408.2M | -570.3M | -213.8M |
| Depreciation & Amortization | 9.9M | 7.9M | 6.9M | 1.4M | 1.4M |
| Stock-Based Compensation | 112.4M | 72.0M | 28.8M | 193.6M | 65.6M |
| Working Capital Changes | -6.4M | 710.0K | 4.9M | 5.9M | 2.9M |
| Operating Cash Flow | -617.9M | -697.4M | -351.5M | -273.2M | -139.4M |
| Investing Activities | |||||
| Capital Expenditures | -715.0K | -4.0M | -3.0M | -6.1M | -938.0K |
| Acquisitions | - | - | 0 | 0 | 1.9M |
| Investment Purchases | -266.9M | -745.7M | -194.1M | -263.7M | 0 |
| Investment Sales | 570.0M | 504.4M | 327.0M | 0 | 0 |
| Investing Cash Flow | 300.6M | -245.4M | 129.8M | -269.8M | 944.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 250.0M | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 437.3M | 666.3M | 211.9M | 767.6M | 138.4M |
| Free Cash Flow | -610.2M | -586.5M | -334.8M | -338.8M | -146.8M |
| Net Change in Cash | 119.9M | -276.5M | -9.7M | 224.6M | 3.0K |
Cash Flow Trend
Biohaven Key Financial Ratios
Valuation Ratios
Forward P/E
-5.26
Price to Book
26.84
PEG Ratio
-5.26
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-310.75%
Return on Assets
-83.02%
Financial Health
Current Ratio
3.18
Debt to Equity
546.58
Beta
3.62
Per Share Data
EPS (TTM)
$-6.86
Book Value per Share
$0.39
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BHVN | 1.5B | - | 26.84 | -310.75% | 0.00% | 546.58 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Amylyx | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.






